Another method involves examining the effect of combinations on nuclear localization of proteins relevant to NHL, and testing combinations on different types of high-grade lymphomas such as those with BCL-2 and c-Myc rearrangements to determine their efficacy in the context of features that drive aggressive disease subtypes. The gene discussed is MYC; the disease is non-Hodgkin lymphoma.